Bioxyne reports the results from the Phase IIb COPD study
29-Jun-2012 -
Bioxyne Limited has received the preliminary analysis of the study 005 which examines the efficacy and safety of the immunotherapeutic, HI 164 OV in patients with chronic obstructive pulmonary disease (COPD).The study recruited 320 patients from 21 sites around Australia. At study’s end 287 ...
chronic obstructive pulmonary disease
phase IIb studies